|
Match
|
Document |
Document Title |
|
|
7384643 |
Recombinant poxvirus
Use for novel chemokine-binding protein designated A41L, and chemokine-binding fragments thereof, for the treatment of conditions such as inflammation. The A41L protein binds to chemokines in the...
|
|
|
7344722 |
Cold-adapted influenza virus
The cold-adapted master strain A/Ann Arbor/6/60 7PI (H2N2) and progenitor wild type E2(3) viral strains have been deposited and their genomic sequences identified. Seven nucleotide differences were...
|
|
|
7332170 |
Classical swine fever virus virulence determinant and a novel classical swine fever vaccine
Transposon linker insertion mutagenesis of a full-length infectious clone of the highly pathogenic classical swine fever virus (CSFV) isolate Brescia (pBIC) was used to identify genetic...
|
|
|
7316813 |
Influenza vaccine composition
An inactivated influenza virus preparation is described which comprises a haemagglutinin antigen stabilized in the absence of thiomersal, or at low levels of thiomersal, wherein the haemagglutinin...
|
|
|
7303754 |
MVA expressing modified HIV envelope, gag, and pol genes
The invention provides modified virus Ankara (MVA), a replication-deficient strain of vaccinia virus, expressing human immunodeficiency virus (HIV) env, gag, and pol genes.
|
|
|
7262045 |
Methods of producing influenza vaccine compositions
Methods and compositions for the optimization of production of influenza viruses suitable as influenza vaccines are provided.
|
|
|
7250171 |
Construction and use of recombinant parainfluenza viruses expressing a chimeric glycoprotein
Chimeric parainfluenza viruses (PIVs) are provided that incorporate a PIV vector genome or antigenome modified to encode a chimeric glycoprotein incorporating one or more heterologous antigenic...
|
|
|
7244434 |
Replicons of pestviruses that do not express C and or E1 protein and infectious viral particles containing same, that can be used in vaccines
The present invention provides new Pestiviral RNA genomes (replicons) that are able to replicate, and can be packaged into infectious viral particles in cells that complement the missing...
|
|
|
7229625 |
Retrovirus-like particles made non-infectious by a plurality of mutations
Non-infectious, retrovirus-like particles contain mutations to reduce gag-dependent RNA-packaging of the gag gene product, eliminate reverse transcriptase activity of the pol gene product,...
|
|
|
7229624 |
Ordered molecular presentation of antigens, method of preparation and use
The invention provides compositions and processes for the production of ordered and repetitive antigen or antigenic determinant arrays. The compositions of the invention are useful for the...
|
|
|
7201911 |
Cloned genomes of infectious hepatitis C viruses and uses thereof
The present invention discloses nucleic acid sequences which encode infectious hepatitis C viruses and the use of these sequences, and polypeptides encoded by all or part of these sequences, in the...
|
|
|
7198934 |
Recombinant MVA virus, and the use thereof
The present invention relates to recombinant vaccinia viruses derived from the modified vaccinia virus Ankara (MVA) and containing and capable of expressing foreign genes which are inserted at the...
|
|
|
7182947 |
Papillomavirus truncated L1 protein and fusion protein constructs
Vaccine formulations comprising viral capsomeres are disclosed along with methods for their production. Therapeutic and prophylactic methods of use for the vaccine formulations are also disclosed.
|
|
|
7179473 |
Attenuated pestiviruses
This invention relates to attenuated pestiviruses characterised in that their enzymatic activity residing in glycoprotein E RNS is inactivated, methods of preparing, using and detecting these.
|
|
|
7132106 |
Infectious cDNA clone of North American porcine reproductive and respiratory syndrome (PRRS) virus and uses thereof
The invention provides isolated polynucleotide molecules, including plasmids; viral vectors; and transfected host cells that comprise a DNA sequence encoding an infectious RNA sequence encoding a...
|
|
|
7108855 |
Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
The present invention relates to a method for purifying recombinant HCV single or specific oligomeric envelope proteins selected from the group consisting of E1 and/or E2 and/or E1/E2,...
|
|
|
7094411 |
Avirulent, immunogenic flavivirus chimeras
Chimeric flaviviruses that are avirulent and immunogenic are provided. The chimeric viruses are constructed to contain amino acid mutations in the nonstructural proteins of a flavivirus. Chimeric...
|
|
|
7074410 |
Modified HCV peptide vaccines
Provided are an isolated peptide having the amino acid sequence DLMGYIPAV (SEQ ID NO: 1), an isolated HCV core polypeptide comprising an L→A substitution at amino acid position 139, an isolated...
|
|
|
7063851 |
Herpes viruses for immune modulation
A method of stimulating an immune response in a human or animal subject, which method comprises administering to a subject in need thereof an effective amount of an attenuated herpes virus which:
...
|
|
|
7063835 |
Virus strains
The present invention relates to non-laboratory virus strains, for example of herpes viruses such as HSV, with improved oncolytic and/or gene delivery capabilities as compared to laboratory virus...
|
|
|
7033797 |
Synthetic virus-like particles with heterologous epitopes
The invention is a series of synthetic virus-like particles comprising a heterologous conformational epitope useful in the characterization of human papillomavirus infection, and useful to...
|
|
|
7026113 |
EIA vaccine and diagnostic
The invention provides an equine infectious anemia (EIA) vaccine that provides immunity to mammals, especially equines, from infection with equine infectious anemia virus (EIAV) and which allows...
|
|
|
7025968 |
CMV vaccines
The invention provides methods and compositions for inhibiting CMV infection and dissemination in an animal, as well as in vitro and in vivo assay systems for identifying such compositions.
|
|
|
7014847 |
Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
The present invention pertains to methods for preventing reovirus recognition in the treatment of cellular proliferative disorders, and particularly ras-mediated cellular proliferative disorders,...
|
|
|
6979448 |
Chimaeric plant viruses with mucin peptides
Mucin peptide epitopes are inserted into the coat protein of a plant virus (e.g., a comovirus such as CPMV) having a beta-barrel structure at an immunogenically effective site, such as in a loop...
|
|
|
6974575 |
Generation of type I/type II hybrid form of bovine viral diarrhea virus for use as vaccine
The present invention provides genetically engineered type I/type II hybrid BVDV viruses. The hybrid viruses, as well as the hybrid viral genome, can be used in immunogenic compositions and...
|
|
|
6964762 |
Composition and method for stimulating immune response to pathogen using complex adenoviral vector
Genetic vaccines and methods are provided for enhancing the immunity of a host such as a human to one or more pathogens. In one aspect, a method of enhancing the immunity of a host to a pathogen is...
|
|
|
6923971 |
Respiratory syncytial virus vaccines expressing protective antigens from promoter-proximal genes
Recombinant respiratory syncytial virus (RSV) having the position of genes shifted within the genome or antigenome of the recombinant virus are constructed by insertion, deletion or rearrangement...
|
|
|
6908762 |
Method of preparing a eukaryotic viral vector
The inventive method of producing a eukaryotic viral vector comprises contacting a eukaryotic cell, which comprises a unique enzyme that nicks or cleaves a DNA molecule, with a recombinant phage...
|
|
|
6908618 |
Production of novel bovine respiratory syncytial viruses from cDNAs
A method of producing an attenuated bovine respiratory syncytial virus (BRSV) having increased or decreased transcription and/or replication, as compared to a wild-type BRSV, including the steps of...
|
|
|
6908617 |
Glycosylated modified primate lentivirus envelope polypeptides
A modified polypeptide corresponding to an envelope glycoprotein of a primate lentivirus is described. The polypeptide has been modified from the wild-type structure so that it has at least two of...
|
|
|
6849429 |
Viral pseudo-capsids including assembly agonists and antagonists
Recombinant hepatitis C virus (HCV) capsid proteins that self-assemble into large spherical virus-like particles structures and viral capsids that include conformational antigenic epitopes are...
|
|
|
6841373 |
Herpes virus complementing cell line
The present invention is directed to a cell line capable of supporting replication of a growth-defective Herpes Simplex Virus strain; specifically a replication-defective HSV-2 double mutant....
|
|
|
6841157 |
Production of chimeric human papillomavirus
This invention relates to infectious chimeric papillomaviruses, and especially those where the early genes are from human papillomavirus (HPV) 18, and the late genes are from another HPV. Also...
|
|
|
6723316 |
Herpes simplex virus-1 Glycoprotein C mutants for treating unwanted hyperproliferative cell growth
The present invention relates to pharmaceutical compositions, kits, and methods of use thereof, comprising, a mutant human herpes simplex virus, which is cytopathic to susceptible target cells,...
|
|
|
6713067 |
Herpes viruses for immune modulation
An attenuated herpes virus which lacks a functional vhs gene or a functional equivalent thereof, but which has a functional UL43 gene or functional equivalent thereof, stimulates an immune response...
|
|
|
6699476 |
Production of recombinant respiratory syncytial viruses expressing immune modulatory molecules
Recombinant respiratory syncytial virus (RSV) are provided which express one or more immune modulatory molecules. The recombinant virus is modified by addition or substitution of a polynucleotide...
|
|
|
6680060 |
Hepatitus A virus vaccines
A live hepatitis A virus adapted to growth in MRC-5 cells, which HAV is preferably characterized by suitable attenuation for effective vaccine administration to humans and animals without...
|
|
|
6673602 |
Herpes simplex virus amplicon vector targeting system and method of using same
The present invention relates to herpes simplex virus (HSV) amplicon vectors, and in particular, HSV-1 amplicon vectors, which have been genetically modified and used alone or with consequent...
|
|
|
6660264 |
Treatment of intracellular infection
An agent for combating an intracellular microbial infection comprises a phage component and, associated therewith, a targeting moiety which directs the agent to a target cell and initiates delivery...
|
|
|
6641817 |
Herpes virus vectors for dendritic cells
An attenuated herpes virus capable of efficiently infecting a dendritic cell without preventing antigen processing occurring within the infected cell. The attenuated herpes virus and dentrictic...
|
|
|
6641816 |
Use of poxviruses as enhancer of specific immunity
The invention relates to a method for enhancing the specific immune response against an immunogenic compound which comprises administering the immunogenic compound together with a poxvirus...
|
|
|
6635472 |
Retrovirus and viral vectors
This invention relates to the fields of genetic engineering, virus replication and gene transfer. More specifically, this invention relates to polynucleotide construct, recombinant virus,...
|
|
|
6605284 |
Gene coding for the measles virus mutant antigen
Disclosed is a measles virus mutant gene coding for a measles virus mutant H protein antigen, wherein said gene coding for a measles virus mutant H protein antigen is at least one member selected...
|
|
|
6592871 |
HCV peptide antigens and methods for the determination of HCV
Novel HCV peptide antigens are described representing partial sequences of the C-100-3 and env/core with C-regions. These peptide antigens are suitable for the determination of HCV antibodies as...
|
|
|
6589533 |
Genetically-engineered alphaviruses, flaviviruses, and bunyaviruses with modified envelope transmembrane glycoproteins and altered host-range phenotype
The present invention is directed toward genetically-engineered, membrane-enveloped Alphaviruses, Flaviviruses, and Bunyaviruses containing modified viral transmembrane envelope glycoproteins...
|
|
|
6569422 |
Genetically engineered cell culture adapted infectious bursal diseases virus (IBDV) mutants
The present invention relates to a method for the adaptation of infectious bursal disease viruses (IBDV) to growth in CEF cell culture. Changing the codons for amino acid residues 253 (Gln) and 284...
|
|
|
6562351 |
Papilloma truncated L1 protein and fusion protein constructs
Vaccine formulations comprising viral capsomeres are disclosed along with methods for their production. Therapeutic and prophylactic methods of use for the vaccine formulations are also disclosed.
|
|
|
6544526 |
Equine herpesvirus glycoproteins
A vaccine for the selective immunization of horses against EHV4 and/or EHV1 is provided comprising at least one of (i) EHV4 virus wherein a portion of the gG gene of the EHV4 virus that elicits a...
|
|
|
6541009 |
Viral vaccines
A mutant virus for use as a vaccine, wherein the genome of the virus is defective in respect of a gene essential for the production of infectious virus. In one aspect the mutant virus is capable of...
|